NCT03964051: Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana).
- State
- Stopped early
- Phase
- Phase 4
- People
- 7 taking part
- Started
- 1 Jul 2019
- Primary completion
- 21 Dec 2020
- Arms
- Omalizumab 300 mg for s.c.injection
- Results
- None posted
- 28 May 2019: Trial registered
- 1 Jul 2019: Trial started
- 21 Dec 2020: Trial terminated